Danaher Q4 Results Beat Expectations, Clocks 21% Jump In Sales

Danaher Corporation DHR logged Q4 FY21 adjusted EPS of $2.69 up 29% Y/Y, surpassing the estimate of $2.51.

  • Sales increased 20.5% to $8.1 billion, with 19.5% non-GAAP core revenue growth, beating the $7.92 billion estimate.
  • Operating cash flow for FY21 reached $8.4 billion, representing a Y/Y increase of 34.5%. Non-GAAP free cash flow increased 30.5% at $7.1 billion.
  • The gross margin expanded to 60.7% from 58.5% a year ago, and the operating margin also improved from 23.7% to $26.4%.
  • Rainer Blair, President & CEO, stated, "2021 was a tremendous year for Danaher. Our team successfully executed through a challenging environment to deliver outstanding financial results — including 25% core revenue growth, nearly 60% adjusted earnings per share growth, and over $7 billion of free cash flow." 
  • Blair also added, "we were particularly pleased with the performance in our base business, which grew low-double digits, and believe we gained market share across our portfolio. We also continued to build for the future, deploying $11 billion on strategic acquisitions while accelerating innovation and capacity investments."
  • Outlook: For both Q1 FY22 and FY22, Danaher anticipates that non-GAAP core revenue growth in the base business will be in the high-single-digit percent range.
  • Analyst Reaction: Barclays has lowered the price target from $355 to $325 with the Overweight rating unchanged.
  • Price Action: DHR shares closed at $266.82 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!